There are several inaccuracies in your comment. Infusion reactions to paclitaxel are rare and not serious. Most of the toxicity arises from cumulative nerve damage with chronic use.
There is also no evidence it promotes cancer recurrence.
There is also no evidence it promotes cancer recurrence.
I say toxic relative to the Benzimidazole family of medication, and though Paclitaxel’s worst side effects, like the neuropathy you mention, come cumulatively with chronic use, it’s more common side effects are still numerous, including a few serious ones, from sources I find.
And “promotes cancer recurrence” was a poor choice of term on my part. What I mean here is the time between doses is wide enough to permit recurrence in some cases.